These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36529836)

  • 1. Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease.
    Sy SKB; Tanaka C; Grosch K
    Clin Pharmacokinet; 2023 Feb; 62(2):249-266. PubMed ID: 36529836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease.
    Kanter J; Brown RC; Norris C; Nair SM; Kutlar A; Manwani D; Shah N; Tanaka C; Bodla S; Sanchez-Olle G; Albers U; Liles D
    Blood Adv; 2023 Mar; 7(6):943-952. PubMed ID: 36355805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
    Ataga KI; Kutlar A; Kanter J; Liles D; Cancado R; Friedrisch J; Guthrie TH; Knight-Madden J; Alvarez OA; Gordeuk VR; Gualandro S; Colella MP; Smith WR; Rollins SA; Stocker JW; Rother RP
    N Engl J Med; 2017 Feb; 376(5):429-439. PubMed ID: 27959701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizanlizumab: First Approval.
    Blair HA
    Drugs; 2020 Jan; 80(1):79-84. PubMed ID: 31933169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.
    Kutlar A; Kanter J; Liles DK; Alvarez OA; Cançado RD; Friedrisch JR; Knight-Madden JM; Bruederle A; Shi M; Zhu Z; Ataga KI
    Am J Hematol; 2019 Jan; 94(1):55-61. PubMed ID: 30295335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment.
    Man Y; Goreke U; Kucukal E; Hill A; An R; Liu S; Bode A; Solis-Fuentes A; Nayak LV; Little JA; Gurkan UA
    Blood Cells Mol Dis; 2020 Jul; 83():102424. PubMed ID: 32208292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report.
    Afana MS; Abu-Tineh M; Alshurafa A; Yasin AK; Ahmed K; Abdulgayoom M; Yassin MA
    Hematology; 2023 Dec; 28(1):2229115. PubMed ID: 37519115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel.
    Kanter J; Ataga KI; Bhasin N; Guarino S; Kutlar A; Lanzkron S; Manwani D; McGann P; Stowell SR; Tubman VN; Yermilov I; Campos C; Broder MS
    Ann Hematol; 2024 Jun; 103(6):1909-1917. PubMed ID: 38642304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful Treatment of SCD-Related Priapism With Crizanlizumab: A Case Series.
    Idowu M; Garcia RL; Sule OB
    J Investig Med High Impact Case Rep; 2023; 11():23247096231191873. PubMed ID: 37731262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease.
    Stevens DL; Hix M; Gildon BL
    J Pharm Technol; 2021 Aug; 37(4):209-215. PubMed ID: 34752581
    [No Abstract]   [Full Text] [Related]  

  • 12. Crizanlizumab in vaso-occlusive crisis caused by sickle cell disease.
    Gardner RV
    Drugs Today (Barc); 2020 Nov; 56(11):705-714. PubMed ID: 33332478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical evaluation of crizanlizumab for the treatment of sickle cell disease.
    Karki NR; Saunders K; Kutlar A
    Expert Rev Hematol; 2022 Jan; 15(1):5-13. PubMed ID: 34942078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world experience of patients with sickle cell disease treated with crizanlizumab.
    Chan KH; Buddharaju R; Idowu M
    J Investig Med; 2024 Feb; 72(2):242-247. PubMed ID: 38073007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world characteristics of patients with sickle cell disease who initiated crizanlizumab therapy.
    Desai PC; Chen CC; McGuiness CB; Yasuda M; Lee S; Paulose J; He J; Yen G
    Curr Med Res Opin; 2023 Apr; 39(4):555-565. PubMed ID: 36883332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar's healthcare perspective.
    Adel AM; Abushanab D; Al-Badriyeh D; Hamad A; Alshurafa A; Yassin MA
    SAGE Open Med; 2024; 12():20503121231224551. PubMed ID: 38711465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study.
    Liles DK; Shah NR; Scullin B; Gordeuk VR; Smith WR; Kanter J; Achebe MM; Boccia R; Crary SE; Kraft WK; Archer N; Cataldo V; Hardesty BM; Idowu M; Desai PC; Ikeda A; Puthenveetil G; Hassell KL; Sarnaik S; Kutlar A
    Br J Haematol; 2021 Nov; 195(4):e150-e153. PubMed ID: 34611900
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease.
    Mayer CL; Koeck K; Hottmann M; Redfern A; Davis M; Barth A; Geng X; Hoppe C; Yue P
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1219-1228. PubMed ID: 37436495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis.
    Thom H; Jansen J; Shafrin J; Zhao L; Joseph G; Cheng HY; Gupta S; Shah N
    BMJ Open; 2020 Sep; 10(9):e034147. PubMed ID: 32948541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease.
    Delgado J; Voltz C; Stain M; Lapveteläinen T; Urach S; Lähteenvuo J; Penttilä K; Gisselbrecht C; Enzmann H; Pignatti F
    Hemasphere; 2021 Jul; 5(7):e604. PubMed ID: 34235401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.